Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a prominent player in the pharmaceutical industry with a market capitalization of $748 billion, will present the primary overall survival analysis from ...

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...

That’s how Ukrainian journalist Dmytro Khyliuk sums up his feelings after his release from three years’ imprisonment in a Russian correctional colony. His homecoming on Ukraine’s Independence Day, Aug ...

Vladimir Putin has staked the fate of his presidency, and Russian imperial ambitions, on the outcome of the war in Ukraine. Russia’s war on Ukraine was never really about NATO expansion or Western ...

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 2 years. On August 27, Eli Lilly and Company announced that its drug, Verzenio (abemaciclib), combined with ...